

# 4 soho Italy

SOCIETY OF HEMATOLOGIC ONCOLOGY

## 2022 ANNUAL CONFERENCE

### HYBRID EVENT



**JOIN US!**

Free registration

[www.sohoitaly.com](http://www.sohoitaly.com)

**23 - 24 - 25 - 26 Oct 2022**

A. Roma Lifestyle Hotel

**Rome, Italy**



Organizing secretariat



[www.proeventi.it](http://www.proeventi.it)  
[info@proeventi.it](mailto:info@proeventi.it)

**18.2 CME credits for:**

Physicians, Biologists, Biomedical laboratory technicians,  
Pharmacists, Nurses

Follow us

**#SOHOItaly2022**





## Italian ECM Accreditation

The Conference has been accredited to the Italian Ministry of Health:

Event n. 2773 - 359941

Provider n. 2773

ECM Credits n.18.2 for:

Medical Surgeon (interdisciplinary area), Biologist, Pharmacist, TSLB, Nurse

Training objective 3: Clinical documentation. Diagnostic and rehabilitation clinical-care pathways, care profiles - treatment profiles.

Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.



## EBAH CME Accreditation

Continuing Medical Education (CME) is widely accepted to encourage individual practitioners to maintain and develop professional knowledge and skills keeping up-to-date with latest developments within the field. The meeting is accredited by the EBAH system. Participants of this meeting will receive 24 Credits following the entire Conference (23-26 Oct. 2022)



## Patronage



ALLEANZA  
CONTRO  
IL CANCRO



ASSOCIAZIONE ITALIANA  
CONTRO LEUCEMIE  
LINFOMI E MIELOMA



Associazione Italiana di Oncologia Medica



ATRC



FONDAZIONE  
ITALIANA  
LINFOMI



GRUPPO ITALIANO PER IL TRATTAMENTO DI MIELOLODIPLOCLASTI, CELLULE STAMINALI EMPOIETICHE E TERAPIA CELLULARE



istituto  
oncologico  
romagnolo  
vicino a chi soffre,  
insieme a chi cura



Ordine  
Nazionale  
Biologi



Società Italiana  
di Ematologia




SOCIETÀ ITALIANA DI FARMACOLOGIA

## In Association with



society of hematologic oncology

## Promoted by



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO  
ROMAGNOLO  
PER LO STUDIO  
DEI TUMORI  
DINO AMADORI

00000000 000000 0000  
000000 000000 00 00  
00000000 000 00000  
0000 000000 00  
0 00 0000 0000 000

- BUSINESS  
- NETWORKING  
- SOCIAL NETWORK  
- TECHNOLOGY  
- MEDIA  
- CREATIVE  
- FINANCE  
- INVESTMENT  
- CULTURE  
- ECONOMY


provider n. 2773



info@proeventi.it  
www.proeventi.it



## A hand is shown from the bottom, holding a glowing, translucent digital network structure. The structure consists of white dots connected by thin white lines, forming a complex web. The background is a solid blue color. In the top right corner, there is a grid of white binary code (0s and 1s). The overall image conveys a sense of technology, connectivity, and human interaction with digital systems.



## What is SOHO Italy?

The Italian Society of Hematologic Oncology is bringing together leading SOHO experts and top Italian researchers in acute leukemias, MPDs and MDSs, aims to consolidate the Italian Hematology-SOHO partnership.

## Purpose

The aim of the association is the integration of the clinical-scientific activities of Italy and MD Anderson Cancer Center and the improvement of the clinical-therapeutic approach to patients with hematologic malignancies.

## Represented by

The Society SOHO Italy is represented by G. Martinelli and C. Cerchione, IRST Meldola, and H. Kantarjian, E. Jabbour, M. Konopleva, N. Daver, MD Anderson Cancer Center.



# PRESIDENTS

## Claudio Cerchione



Since 2018, he works in Hematology Unit of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS. He also has spent international research experiences in Friedrich-wilhelms universität, Bonn, Germany, in Universidade de Coimbra, Portugal, collaborating in their clinical and research projects, and in MD Anderson Cancer Center, Houston, USA, where he was nominated Ambassador of SOHO (Society of Hematologic Oncology). He is member of the editorial boards of many scientific journals, and member of several international societies, including the Society of Hematologic Oncology (SOHO), American Society of Hematology (ASH), European Hematology Association (EHA) and Italian Society of Hematology (SIE).

## Hagop Kantarjian



Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute. Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A. Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003 - present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian's research focuses on translational-clinical developmental therapeutics.

## Giovanni Martinelli



As of 1 January 2018, Professor Giovanni Martinelli is scientific director of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS, in Meldola (FC), Italy. Until December 2017, Professor Giovanni Martinelli was associate professor of Hematology at the Institute of Hematology "L. & A. Seragnoli", Azienda Ospedaliera S. Orsola - Malpighi at the University of Bologna, Italy. His main fields of research are AML, ALL and CML, including research on targeted therapies in major hematological syndromes: Acute Leukemias, CML (both Philadelphia-chromosome positive and non - positive), and hypereosinophilic syndrome.





# SCIENTIFIC BOARD

Claudio Cerchione, Hagop Katarjian, Giovanni Martinelli

## Kenneth C. Anderson



Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

## Naval G. Daver



Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He is a clinical investigator with a focus on molecular and immune therapies in AML and myeloid disease and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance.

## Courtney DiNardo



Dr. DiNardo interests are focused on inherited predispositions to hematologic malignancies. This interest led to the development of one of the first dedicated clinics for evaluation of families with hematologic malignancies in the country (Hereditary Hematologic Malignancy Clinic—HHMC) in April 2014.

The HHMC provides research based opportunities for scientific discovery through whole exome sequencing families with a strong history of hematologic malignancies including the potential for novel gene discovery. My research in the evolving clinical phenotype and treatment outcomes of IDH1 and IDH2 mutations in myeloid malignancies has yielded numerous publications and national/international IDH-inhibitor trials.



## Alessandra Ferrajoli



Dr. Ferrajoli is an academic hematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson since 1998. Her main area of interest includes the treatment and biology of chronic lymphocytic leukemia and its variants, and treatment of elderly patients with acute and chronic leukemia. In these fields Dr. Ferrajoli has authored and co-authored more than two hundred and fifty publications in peer reviewed journals. She serves on numerous journal editorial boards and grant proposal study sessions for several US and European Agencies.

## Nathan H. Fowler



His interest in immunomodulatory agents began during my hematology/oncology fellowship at Georgetown University Hospital, where he helped to develop some of the first protocols to use lenalidomide in CLL. Since joining the faculty at MD Anderson Cancer Center, the goal of his clinical research has been to further develop novel therapeutic regimens utilizing immunomodulatory agents to benefit patients with low grade non-Hodgkins lymphoma. He serves as the chairman of several phase I and investigator-initiated phase II trials for patients with non-Hodgkins lymphoma which includes leading the largest clinical study to use immunomodulatory drugs for untreated low grade lymphoma.

## Guillermo Garcia-Manero



Guillermo Garcia-Manero, M.D., is a physician-scientist specializing in state-of-the-art treatments for leukemia. His research focuses on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and his goal is develop and validate new therapeutics to treat these deadly diseases. He leads teams of clinicians, medical fellows, nurses, physician assistants and researchers to conduct pre-clinical, translational, and clinical studies. The goal of these studies is to understand, treat, and eventually cure MDS, AML and other leukemias.



## Elias Jabbour



Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; 5) triple therapy in AML.

## Hans C. Lee



Hans C. Lee, MD, is an Assistant Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas where he focuses his efforts on the clinical care and research of patients with plasma cell dyscrasias. He has a particular interest and focus on early phase clinical trials and novel therapeutic approaches to relapsed and/or refractory multiple myeloma.


## Tapan M. Kadia



Dr. Tapan Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL. He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these.



## Marina Konopleva



Dr. Konopleva is a Physician-Scientist, Professor, and active member of the clinical faculty in the Departments of Leukemia and Stem Cell Transplantation. Her laboratory is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. Dr. Konopleva has extended her research to include clinical translational investigations and has developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs. She has also been an active mentor to trainees including undergraduate, medical and graduate students, post-doctoral fellows who have trained under her direction in support of her various laboratory grants and projects.

## Gerardo Musuraca



Dr. Musuraca is the Chief of Hematology Unit at IRST – IRCCS, in Meldola (FC), Italy. After a degree cum laude at the University of Bologna and a specialization in Hematology, since January 2006 he has been a PhD student in Clinical and Experimental Hematology at the University of Bologna. In 2007 he began the Clinical activity and research at Cancer Institute of Romagna. He is also Abstracts Reviewer and moderator on lymphoma, preclinical and biological agents of the American Society of Hematology meeting (ASH) and in December 2011 he reached a highly specialized position on Lymphomas at the Cancer Institute of Romagna. Dr. Musuraca is Coauthor of more than 43 publications and Since 2001 he is involved in more than 200 multicenter national and international clinical trials performed in onco-hematology (Lymphomas), according to the FDA regulations and/or ICH-GCP guidelines.

## Farhad Ravandi-Kashani



Dr. Farhad Ravandi is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas — M. D. Anderson Cancer Center. Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.





## Giuseppe Saglio



Giuseppe Saglio is Full Professor of Internal Medicine and Hematology at the University of Turin. He graduated from the University of Turin in 1975. Since then he has studied Internal Medicine at the University of Turin (1975-1980), Hematology at the University of Milan (1980-1983), and Molecular Biology at the University of Leiden (1976), Inserm-Creteil, Paris (1979) and at the University of California (1983). Prof. Saglio is coordinator of the PhD program in Molecular Medicine at the University of Turin, past-president of the Italian Society of Experimental Hematology (SIES) and is a member of the Academy of Medicine of Turin. He has published more than 280 specialized articles in the field Molecular Pathogenesis of Hematologic Diseases (1986 to present), Molecular Medicine Applied to Clinical Medicine (1978-1990) and Molecular Basis of Thalassemia and Related Hemoglobinopathies (1978-1990).

## Srdan Verstovsek



Dr. Verstovsek is the United Energy Resources, Inc., Professor of Medicine and a hematologist-oncologist at MD Anderson, he is a global leader in myeloproliferative neoplasms (MPN) and the Founder/ Director of the largest MPN Clinical Research Center worldwide. He has achieved international acclaim for his leadership in developing landmark MPN therapeutics. He is leading pivotal phase 3 trials for several promising myelofibrosis medications. Dr. Verstovsek received several distinguished awards, including the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research (2017) and the Seventh Annual Irwin H. Krakoff Award for Excellence in Clinical Research (2013). He was elected member of The American Society for Clinical Investigation (2015) and received the Celgene 2010 Young Investigator Award for Clinical Research.

# SCIENTIFIC SECRETARIAT

Claudio Cerchione, Giovanni Martinelli, Gerardo Musuraca





# FACULTY

Elisabetta **Abruzzese**

Micheal **Andreeff**

Kenneth C. **Anderson**

Mario **Boccadoro**

Niccolo' **Bolli**

Giuliano **Bolondi**

Cirino **Botta**

Lorenzo **Brunetti**

Francesco **Buccisano**

Gabriele **Buda**

Amanda **Cashen**

Fausto **Castagnetti**

Claudio **Cerchione**

Daniela **Cilloni**

Simona **Colla**

Antonio **Cuneo**

Naval **Daver**

Adolfo **De La Fuente**

Matteo **Della Porta**

Enrico **Derenzini**

Daniele **Derudas**

Courtney **DiNardo**

Francesco **Di Raimondo**

Rome

Houston

Boston

Turin

Milan

Meldola (FC)

Palermo

Ancona

Rome

Pisa

St. Louis

Bologna

Meldola (FC)

Turin

Houston

Ferrara

Houston

Madrid

Milan

Milan

Cagliari

Houston

Catania



Massimo **Dominici**

Brunangelo **Falini**

Alessandra **Ferrajoli**

Felicetto **Ferrara**

Anna **Ferrari**

Anna Maria **Frustaci**

Gianluca **Gaidano**

Sara **Galimberti**

Guillermo **Garcia-Manero**

Paolo **Ghia**

Cesarina **Giallongo**

Guido **Gini**

Michele **Gottardi**

Birol **Guvenc**

Ilaria **Iacobucci**

Alessandro **Isidori**

Elias **Jabbour**

Tapan **Kadia**

Hagop **Kantarijan**

Marina **Konopleva**

Francesco **Lanza**

Hans **Lee**

Alessandro **Lucchesi**

Stefano **Luminari**

Michele **Malagola**

Modena

Perugia

Houston

Naples

Meldola (FC)

Milan

Novara

Pisa

Houston

Milan

Catania

Ancona

Castelfranco Veneto (TV)

Adana

Memphis

Pesaro

Houston

Houston

Houston

New York

Ravenna

Houston

Meldola (FC)

Reggio Emilia

Brescia



# FACULTY

Fabio **Malavasi**

Giovanni **Marconi**

Maurizio **Martelli**

Giovanni **Martinelli**

Massimo **Massaia**

Maria Victoria **Mateos**

Massimiliano **Mazza**

Mauricette **Michallet**

Vittorio **Montefusco**

Mohamad **Mohty**

Adrian **Mosquera**

Philippe **Moreau**

Tariq **Mughal**

Gerardo **Musuraca**

Arnon **Nagler**

Jain **Nitin**

Ernesta Paola **Neri**

Esther **Oliva**

Attilio **Olivieri**

Livio **Pagano**

Bruno **Paiva**

Fabrizio **Pane**

Cristina **Papayannidis**

Aneel **Paulus**

Turin

Meldola (FC)

Rome

Meldola (FC)

Cuneo

Salamanca

Meldola

Lyon

Milan

Paris

Madrid

Nantes

Boston

Meldola (FC)

Tel Aviv

Houston

Calgary

Reggio Calabria

Ancona

Rome

Salamanca

Naples

Bologna

Jacksonville





Naveen **Pemmaraju**

Antonello **Pinto**

Nicola **Polverelli**

Concetta **Quintarelli**

Alessandro **Rambaldi**

Farhad **Ravandi**

Jose Maria **Ribera**

Roberto **Ria**

Alessandra **Romano**

Gianantonio **Rosti**

Giuseppe **Saglio**

Antonio Giovanni **Solimando**

Simona **Soverini**

Ayalew **Tefferi**

Carolina **Terragna**

Elisabetta **Todisco**

Steve **Treon**

Srdan **Verstovsek**

Calogero **Vetro**

Giuseppe **Visani**

Maria Teresa **Voso**

Elena **Zamagni**

Houston

Naples

Brescia

Rome

Bergamo

Houston

Badalona

Bari

Catania

Meldola

Turin

Bari

Bologna

Rochester

Bologna

Busto Arsizio (VA)

Boston

Houston

Catania

Pesaro

Rome

Bologna



# ORAL COMMUNICATIONS FACULTY

Gabriella **Cancemi**

Claudio **Cerchione**

Laura **Cicconi**

Francesco **Da Ros**

Naval **Daver**

Andrea **Duminuco**

Eugenio **Galli**

Andrea **Ghelli Luserna Di Rora**

Martina **Ghetti**

Sebastiano **Giallongo**

Ayesha **Ishtiaq**

Enrico **La Spina**

Elisabetta **Lombardi**

Giovanni **Marconi**

Antonio **Matera**

Maria Gabriela **Orellana Chavez**

Cristina **Papayannidis**

Sara **Peruzzi**

Vittoria **Raimondi**

Annarita **Scialdone**

Micol **Silic-Benussi**

Elisabetta **Taiana**

Messina

Meldola (FC)

Roma

Pordenone

Houston

Catania

Roma

Meldola (FC)

Meldola (FC)

Catania

Islamabad

Catania

Pordenone

Meldola (FC)

Milano

Viterbo

Bologna


Perugia

Padova

Perugia

Padova

Milano





# Key Information

## VENUE

A. ROMA LIFESTYLE HOTEL

Via Giorgio Zoega, 59, 00164 Roma, Italy

## MEETING

Sunday, Oct. 23	12.00 - 18.40
Monday, Oct. 24	07.30 - 19.05
Tuesday, Oct. 25	07.30 - 18.50
Wednesday, Oct. 26	07.30 - 17.55

## SOCIAL MEDIA

Soho Italy is active on various social media platform. Follow us on the networks below and get real-time updates:



Facebook: Soho Italy



Twitter: @sohoitaly



Linkedin: Soho Italy



Instagram: sohoitaly

#SOHOItaly

## INTERNET

WiFi is available in all areas.







# General Information

## LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

## CLIMATE

The average temperature is around 16–27 degrees.

## BANKING SERVICE

The official currency in Rome is the Euro. Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 08:30 to 13:30.

## HOTEL INFORMATION

For hotel information and reservations please visit the Hotels & Groups Desk.

## TAXI

The single number to call a taxi is 060609, for other utilities on the taxi service, see [www.060608.it](http://www.060608.it).

The journey to/ from Fiumicino Airport: 48€


The journey to/ from Ciampino Airport: 30€

The rates from Termini railway station to the city centre should cost between € 8 and € 15.





# Public Transport



Termini railway station is 10 km from the hotel.

The hotel is connected to the center of Rome by tram line no. 8.

The nearest tram stop can be reached on foot from the hotel and the tram will take you directly to Piazza Venezia in 15-20 minutes.

A.Roma Lifestyle Hotel also offers a shuttle service to and from the city center, available from 8.30 to 21.00. Reservation required.







# Program Table

Sunday, Oct. 23

08.00

09.00

10.00

11.00

12.00

12.00 - 13.55

13.00

Session 1 · Biology of Acute Myeloid Leukemia

14.00

13.55 - 15.35

15.00

Session 2 · Acute Myeloid Leukemia – Clinical Session 1

16.00

15.35 - 17.20

Session 3 · Acute Myeloid Leukemia – Clinical Session 2

17.00

17.20 - 18.20

**SOHO Italy – EHOJ Joint Symposium**  
From biology to Personalized Medicine in Hematology

18.00

18.20 - 18.40

19.00

AML Oral Communications

20.00

21.00

22



# Program Table

Monday, Oct. 24

07.00

07.30 - 08.30

08.00

Breakfast with the experts

09.00

08.45 - 10.25

Session 4 · Acute Myeloid Leukemia — State of the art

10.00

10.25 - 12.05

11.00

Session 5 · Acute Myeloid Leukemia — State of the art

12.00

12.05 - 14.30

13.00

Session 6 · Myelodysplastic Syndromes Symposium

14.00

14.30 - 16.20

15.00

Session 7 · Chronic Myeloproliferative Neoplasms

16.00

16.20 - 18.00

17.00

Session 8 · Chronic Lymphocytic Leukemia — Clinical Session

18.00

18.00 - 19.05

19.00

Session 9 · Spotlights on rare entities

20.00





# Program Table

Tuesday, Oct. 25

07.00

07.30 - 08.30

08.00

Breakfast with the experts

08.30 - 09.30

09.00

Acute Myeloid Leukemia: How do cancer genomics guide therapeutic choices  
Sponsored Symposium with educational contribution by Servier - *Extra ECM*

09.30 - 11.20

10.00

Session 10 · Acute Lymphoblastic Leukemia

11.00

11.20 - 13.15

12.00

Session 11 · Acute Lymphoblastic Leukemia 2

13.00

13.15 - 15.00

14.00

IME ROUND TABLE Applying New European Guideline Updates in AML:  
Experts Review Current Best Practice in Treatment and Molecular Testing

15.00

15.00 - 16.25

Session 12 · CART in hematological malignancies

16.00

16.25 - 17.20

17.00

Session 13 · Non Hodgkin Lymphoma Clinical Session

17.20 - 18.05

18.00

Session 14 · Spotlights on Hodgkin Lymphoma

18.05 - 18.50

19.00

Session 15 · Non Hodgkin Lymphoma – DLBCL

20.00



# Program Table

Wednesday, Oct. 26

07.00

07.30 - 08.30

08.00

Breakfast with the experts

09.00

08.30 - 10.15

Session 16 · Multiple Myeloma – Biology

10.00

10.15 - 12.00

11.00

Session 17 · Multiple Myeloma – Clinical Session 1

12.00

12.00 - 14.30

13.00

Session 18 · Multiple Myeloma – Clinical Session 2

14.00

14.30 - 16.15

15.00

Session 19 · Old and new targets in Multiple Myeloma

16.00

16.15 - 18.25

17.00

Session 20 · Chronic Myeloid Leukemia – State of the Art

18.00

19.00

20.00



Day 1

23

10·22



## **WELCOME LUNCH**

**12.00** Welcome and Introduction – What is SOHO Italy and next steps  
**C. Cerchione, H. Kantarjian, G. Martinelli**

## **SESSION 1 · BIOLOGY OF ACUTE MYELOID LEUKEMIA**

Chairs: F. Buccisano, S. Galimberti, I. Iacobucci

**12.15** New insights into AML Biology and their concrete and potential impact on treatment  
**I. Iacobucci**

**12.30** Proapoptotic pathways in AML  
**S. Galimberti**

**12.45** From MRD monitoring to MRD-driven treatment in AML  
**F. Buccisano**

**13.00** NPM1-mutated AML: from biology to treatment  
**L. Brunetti**

**13.15** How I diagnose and treat NPM1-mutated AML  
**B. Falini**

**13.30** DISCUSSION

**13.45** **Oral Communication:**  
Targeting novel oncogenic dependencies in Acute Myeloid Leukemia with mutated NPM1  
**S. Peruzzi**



Sunday, Oct. 23

## **SESSION 2 · ACUTE MYELOID LEUKEMIA CLINICAL SESSION 1**

Chairs: A. Nagler, A. Olivieri, G. Visani

**13.55** How we treat high risk AML (therapy related and AML MRC)

**M.T. Voso**

**14.10** Role of allogenic transplantation in the era of novel agents

**A. Olivieri**

**14.25** Allogenic bone marrow transplantation: novel agents-based induction

**F. Lanza**

**14.40** Haploidentical transplants for Acute Leukemia – The European perspective

**A. Nagler**

**14.55** New frontiers in overcoming Environment-Mediated Drug Resistance in AML

**C. Cerchione**

**15.10** DISCUSSION

**15.25** Oral Communication:

Potential role of CIRCPVT1 in the crosstalk between leukemic cells and the immune-microenvironment in Acute Myeloid Leukemia

**M. Gheti**

## **SESSION 3 · ACUTE MYELOID LEUKEMIA CLINICAL SESSION 2**

Chairs: M. Andreeff, A. De La Fuente, C. Giallongo

**15.35** Why we should not forget Glasdegib

**A. De La Fuente**

**15.50** TP53 in Myeloid Leukemias: Targeting the Guardian of the Genome

**M. Andreeff**




**16.05** Present and future Perspectives for Cellular Therapy in AML  
**A. Rambaldi**

**16.20** Maintenance in AML: Trials or reality?  
**M. Gottardi**

**16.35** “Ferrara criteria” in the era of novel agents  
**F. Ferrara**

**16.50** DISCUSSION

**17.05** ELN Special Lecture: European LeukemiaNet Guidelines: past, present and future  
**F. Pane**

**SOHO Italy – EHOOG Joint Symposium**  **EHOG**  
From biology to Personalized Medicine in Hematology  
Chairs: C. Cerchione, B.Guvenc, G. Martinelli, G.Saglio

**17.20** EHOOG-SOHO Italy State of the Art & Next Questions:  
Multiple Myeloma  
**C. Cerchione**

**17.35** EHOOG-SOHO Italy State of the Art & Next Questions:  
Acute Lymphoblastic Leukemia  
**G. Martinelli**

**17.50** EHOOG-SOHO Italy State of the Art & Next Questions:  
Acute Myeloid Leukemia  
**D. Cilloni**

**18.05** EHOOG-SOHO Italy State of the Art & Next Questions:  
Chronic Myeloid Leukemia  
**G. Saglio**





Sunday, Oct. 23

**18.20 Oral Communication:**

A redox-based strategy to overcome resistance to Venetoclax in Acute Myeloid Leukemia

**V. Raimondi**

**18.30 Oral Communication:**

Role of BCOR and DNMT3A cooperation in the epigenetic signature of Acute Myeloid Leukemia

**A. Scialdone**

**18.40 Conclusions and closing remarks Day 1**

**C. Cerchione, G. Martinelli**



Day 2

24

10·22



Monday, Oct. 24

### **07.30 Breakfast with the experts**

#### **08.30 "Michele Baccarani" Lecture:**

The history of Chronic Myeloid Leukemia: from nightmare to the cure

**G. Saglio**

## **SESSION 4 · ACUTE MYELOID LEUKEMIA STATE OF THE ART**

Chairs: T. Kadia, H. Kantarjian, G. Martinelli

**08.45** How I manage Acute Myeloid Leukemia at MD Anderson Cancer Center

**H. Kantarjian**

**09.00** Is All Oral Therapy of AML a Reality for the Future?

**F. Ravandi**

**09.15** Non-Intensive Treatment of Elderly/Unfit Patients with AML

**T. Kadia**

**09.30** FLT3 mutated AML: Moving Towards Cure

**G. Martinelli**

**09.45** Updates in FLT3 inhibitor based therapies in AML

**N. Daver**

### **10.00 DISCUSSION**

#### **10.15 Oral Communication:**

Agile: a global, randomized, double-blind, phase 3 study of Ivosidenib + Azacitidine versus Placebo + Azacitidine in patients with newly diagnosed Acute Myeloid Leukemia with an IDH1 mutation

**C. Cerchione**





## **SESSION 5 · ACUTE MYELOID LEUKEMIA STATE OF THE ART**

Chairs: N. Daver, C. Di Nardo, M. Konopleva

**10.25** IDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy  
**C. D. DiNardo**

**10.40** How I manage BPDCN in MDACC  
**N. Pemmaraju**

**10.55** How I manage BPDCN in Europe and importance of registries  
**G. Marconi**

**11.10** Immune antibodies and Cellular therapies in AML  
**N. Daver**

**11.25** How Do We Overcome Resistance to Venetoclax  
**M. Konopleva**

**11.40** Secondary AML: what's new?  
**A. Isidori**

**11.55 Oral Communication:**  
Pivekimab sunirine (PVEK, IMGN632) triplet with Azacitidine and Venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory aml and reduced infusion related reactions  
**N. Daver**

OPEN COFFEE BREAK

## **SESSION 6 · MYELODYSPLASTIC SYNDROMES SYMPOSIUM**

Chairs: S. Colla, M. Della Porta, G. Garcia Manero

**12.05** New insights in biology of MDS  
**S. Colla**



## **12.20 A Practical Approach to Molecular Pathology of MDS**

**M. Della Porta**

## **12.35 Management of Higher Risk MDS in MDACC: a total approach**

**G. Garcia-Manero**

## **12.50 Treatment of Lower Risk MDS**

**E. Oliva**

## **13.05 DISCUSSION**

## **13.20 LUNCH BREAK**

### **14.00 Oral Communication:**

Select-MDS-1 Trial in progress: a phase 3 randomized, double-blind, placebo-controlled study of Tamibarotene/Azacitidine vs Placebo/Azacitidine in newly diagnosed (ND) adult patients selected for rars-positive HR-MDS

**G. Marconi**

### **14.10 Oral Communication:**

Epigenetic changes in Myelodysplastic Syndrome-Derived mesenchymal stromal cells rewire their inflammatory and metabolic profile

**S. Giallongo**

### **14.20 Oral Communication:**

Therapy-Related Myeloid Neoplasm after Multiple Myeloma in the era of new drugs: a retrospective study

**L. Cicconi**

## **SESSION 7 · CHRONIC MYELOPROLIFERATIVE NEOPLASMS**

Chairs: E. Abruzzese, A. Lucchesi, T. Mughal

## **14.30 Potential New Therapeutic Approaches for Myelofibrosis**

**S. Verstovsek**





**14.45** A new pathogenetic paradigm for MPNs: the “circulating wound”  
**A. Lucchesi**

**15.00** Personalized medicine for MPN patients  
**T. Mughal**

**15.15** How I treat MF candidates for transplant?  
**N. Polverelli**

**15.30** Prognostication and therapy of ET  
**A. Tefferi**

**15.45** Myeloproliferative neoplasms: small molecules in the limelight  
**E. Abruzzese**

**16.00** DISCUSSION

## **SESSION 8 · CHRONIC LYMPHOCYTIC LEUKEMIA CLINICAL SESSION**

Chairs: A. Cuneo, A. Ferrajoli, P. Ghia

**16.15** How I manage CLL at MDACC  
**A. Ferrajoli**

**16.30** Is there still a role for chemoimmunotherapy in Italy?  
**A. Cuneo**

**16.45** Management of relapsed/refractory disease: Novel agents  
**P. Ghia**

**17.00** Role of MRD in CLL  
**M. Massaia**

**17.15** Biology and management of Richter syndrome  
**G. Gaidano**

**17.30** DISCUSSION



**17.45 Oral Communication:**

Anxiety, depression, distress, and resilience in patients with hematological malignancies. Effect of a nine-weeks psychological support on psychological status and stress biological markers

**G. Cancemi**

## **SESSION 9 · SPOTLIGHTS ON RARE ENTITIES**

Chairs: A. Romano, S. Treon, C. Vetro

**17.55** How I manage Waldenstrom Disease in Europe

**A.M. Frustaci**

**18.10** Novel opportunities of Targeted treatment approach for Waldenstrom's Macroglobulinemia

**S. Treon**

**18.25** History and management of AL Amyloidosis

**P. Milani**

**18.40** Novel approaches to treat Advanced Systemic Mastocytosis

**A. Romano**

**18.55 Oral Communication:**

Harbor: a phase 2/3 study of BLU-263 in patients with Indolent Systemic Mastocytosis and Monoclonal Mast Cell Activation Syndrome

**C. Papayannidis**

**19.05** Conclusions and closing remarks Day 2

**C. Cerchione, G. Martinelli**

[illegible]



Day 3

25

10·22



**07.30 Breakfast with the experts****ACUTE MYELOID LEUKEMIA:  
HOW DO CANCER GENOMICS GUIDE  
THERAPEUTIC CHOICES****SERVIER**  
*moved by you*

Sponsored Symposium with educational contribution by Servier  
*Extra ECM - Extra CME*

Chairs: A. De La Fuente, G. Martinelli

**08.30 Chairs' Introduction**

**08.40** Mutation Profiling and Treatment Decisions in AML  
**N. Daver**

**09.00** How to clinically leverage on precision medicine for patients with AML  
**C. DiNardo**

**09.10 Patient Case Discussion****SESSION 10 · ACUTE LYMPHOBLASTIC LEUKEMIA**

Chairs: E. Jabbour, H. Kantarjian, G. Martinelli

**09.30** How I manage Acute Lymphoblastic Leukemia at MDACC  
**H. Kantarjian**

**09.45** How I manage Acute Lymphoblastic Leukemia in Europe  
**G. Martinelli**

**10.00** How I manage Elderly ALL at MDACC  
**E. Jabbour**

**10.15** Approach to Ph-Positive and Ph-Like ALL  
**C. Papayannidis**

**10.30** The management of infectious complications during target therapies in Leukemia patients  
**L. Pagano**





Tuesday, Oct. 25

## 10.45 DISCUSSION

### 11.00 Oral Communication:

MTOR inhibition overcomes Venetoclax resistance in pediatric T-Cell Lymphoblastic Leukemia

**L. Urso**

### 11.10 Oral Communication:

Verapamil and Everolimus cooperate in controlling the proliferation and cell death of t-all cells by altering ros homeostasis

**M. Silic-Benussi**

OPEN COFFEE BREAK

## SESSION 11 · ACUTE LYMPHOBLASTIC LEUKEMIA 2

Chairs: D. Cilloni, A. De La Fuente, J. Ribera

**11.20** Fusion landscape in Acute leukemias: a submerged group of not routinely characterized transcripts

**A. Ferrari**

**11.35** Impact of new immunotherapy and gene therapy for Bcp-ALL patients

**C. Quintarelli**

**11.50** How monoclonal antibodies have changed the outcome of ALL patients

**D. Cilloni**

**12.05** CAR-T Cell in Adult ALL: what's new?

**J. Nitin**

**12.20** CAR-T versus allogenic stem cell transplantation

**J. Ribera**

**12.35 Special Lecture** The model of target therapy:

How I manage CML: State of the art at MDACC

**E. Jabbour**



## 12.50 DISCUSSION

### 13.05 Oral Communication:

Enhance Inotuzumab-Ozogamicin efficacy through PARP1 inhibition against Acute Lymphoblastic Leukemia cells

**A. Ghelli**

## LUNCH TIME ROUND TABLE CLINICAL CARE OPTIONS

**Applying New European Guideline Updates in AML:  
Experts Review Current Best Practice in Treatment  
and Molecular Testing**



powered by CEA

### 13.15 Welcome and Introduction

**13.30** Importance of molecular testing in AML and practical considerations for clinical practice

**13.45** Overview of new and revised European LeukemiaNet Working Party guidelines

**14.00** Treatment options for the most common targetable biomarkers for AML: FLT3, IDH1, and IDH2

**14.15** Coordinating testing, treatment, adverse event management and monitoring for progression

**14.30** Panel discussion: Putting guidelines into clinical practice

**14.45** Audience Question and Answer

## SESSION 12 · CART IN SOLID AND HEMATOLOGICAL MALIGNANCIES

Chairs: M. Dominici, M. Mazza, E. Todisco

**15.00** CAR-T in solid tumors – where we are...and where are we going?  
**M. Dominici**



**15.15** CAR-T and Alleanza contro il cancro: importance of network  
**M. Mazza**

**15.30** The dark side of CAR-T: the point of view from reanimation room  
**G. Bolondi**

**15.45** DISCUSSION

**16.00** Oral Communication:

Endothelial activation and consumptive coagulopathy after treatment with Car-T cells

**E. Galli**

**16.10** Special Lecture from SOHO France 

Therapy-related AML: CHIP documentation in cancer, new perspectives in prognosis and treatment

**M. Michallet**

## **SESSION 13 · NON HODGKIN LYMPHOMA CLINICAL SESSION**

Chairs: N. Fowler, S. Luminari, G. Gini

**16.25** How I manage Follicular and marginal zone Lymphoma  
**S. Luminari**

**16.40** Management and Novel Treatment Approaches in MCL  
**G. Gini**

**16.55** Oral Communication:

Monocyte-to-platelets ratio is associated with inferior outcome in patients with Mantle Cell Lymphoma: a multi-centre real-life survey

**A. Duminuco**



## **SESSION 14 · SPOTLIGHTS ON HODGKIN LYMPHOMA**

Chairs: A. Cashen, A. Pinto

**17.05** Management Hodgkin Lymphoma in Europe  
**A. Pinto**

**17.20** How I manage Hodgkin in Disease in USA  
**A. Cashen**

**17.35** DISCUSSION

## **SESSION 15 · NON HODGKIN LYMPHOMA – DLBCL**

Chairs: E. Derenzini, G. Musuraca

**17.50** How I manage Diffuse Large B-Cell Lymphoma  
**G. Musuraca**


**18.05** The Next Generation of Novel Agents in Development for Aggressive B Cell Lymphoma  
**E. Derenzini**

**18.20** How I manage primary mediastinal Lymphoma  
**M. Martelli**

**18.35** DISCUSSION

**18.50** Conclusions and closing remarks Day 3  
**C. Cerchione, G. Martinelli**





Monday, Oct. 24

[illegible]



Day 4

26

10·22



**07.30 Breakfast with the experts**

**SESSION 16 · MULTIPLE MYELOMA – BIOLOGY**

Chairs: N. Bolli, E.P. Neri, B. Paiva

**08.30** Immunogenomic research in myeloma: from bench to bedside  
**B. Paiva**

**08.45** MRD Assessments in MM - Should We? When? Why?  
**C. Terragna**

**09.00** Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?  
**N. Bolli**

**09.15** Role of BM microenvironment in Myeloma progression and response to immune-based therapies  
**E.P. Neri**

**09.30** Targeting the bone marrow microenvironment in Multiple Myeloma  
**C. Botta**

**09.45** New insights in anti-angiogenesis in Multiple Myeloma  
**R. Ria/A. Solimando**

**10.00** DISCUSSION

OPEN COFFEE BREAK

**SESSION 17 · MULTIPLE MYELOMA  
CLINICAL SESSION 1**

Chairs: K.C. Anderson, C. Cerchione, M.V. Mateos

**10.15** Special Lecture IMS:  
Multiple myeloma cured in 2030: what are the next steps?  
**K.C. Anderson**



**10.45 Multiple Myeloma: State of the art in Europe**  
**C. Cerchione**

**11.00 Smoldering Multiple Myeloma: State of the art**  
**M.V. Mateos**

**11.15 Novel BCMA Targeted ADCs, Bispecific and Trispecific Antibodies**  
**H.C. Lee**

**11.30 EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up in Multiple Myeloma: what is changing?**  
**P. Moreau**

**11.45 DISCUSSION**

**12.00 Special Lecture EMN:**  
Making the history of Multiple Myeloma in EMN Clinical Trials: where we are and where are we going  
**M. Boccadoro**

## **SESSION 18 · MULTIPLE MYELOMA**

### **CLINICAL SESSION 2**

Chairs: M. Boccadoro, C. Cerchione, H.C. Lee

**12.15 Frontline Therapy: Transplant Eligible - How to Choose Agents**  
**E. Zamagni**

**12.30 Frontline Therapy: Transplant Ineligible - How to Choose Agents**  
**V. Montefusco**

**12.45 How I manage extramedullary disease and plasma cell leukemia**  
**D. Derudas**

**13.00 Are innovative therapies helpful also for the frail patients?**  
**G. Buda**

**13.15 Sequencing Agents in Early Relapsed MM**  
**F. Di Raimondo**





### **13.30 DISCUSSION**

### **13.45 LUNCH BREAK**

#### **14.30 Oral Communication:**

Activation of LNCRNA NEAT1 leads to survival advantage of Multiple Myeloma cells by supporting a positive regulatory loop with dna repair proteins

**E. Taiana**

#### **14.40 Oral Communication:**

Ferroptosis as a new BCMA-Targeted immunotherapy off-target effect in Multiple Myeloma

**E. La Spina**

#### **14.50 Oral Communication:**

Single cell RNA sequencing for detection of clonotypic V(D)J rearrangements in Multiple Myeloma

**A. Matera**

## **SESSION 19 · OLD AND NEW TARGETS IN MULTIPLE MYELOMA**

Chairs: F. Malavasi, M. Mohty, A. Paulus

**15.00** Time for new targets: Bench-to-Bedside Development of a unique Bcl-2 inhibitor for Treatment of Multiple Myeloma

**A. Paulus**

**15.15** CD38 in basic science and clinical practice: reflecting on the past to move to the future

**F. Malavasi**

**15.30** CD38 in clinical practice: reflecting on the past to move to the future

**M. Mohty**



**15.45** Novel machine learning applications for MM prognostication

**A. Mosquera**

**16.00** DISCUSSION

**16.15 Oral Communication:**

SRY-BOX transcription factor 4 as a target for Multiple Myeloma new therapeutic strategy

**E. Lombardi**

**16.25 Oral Communication:**

CD20 Positive Multiple Myeloma: monocentric experience and revision of literature

**M. G. Chavez Orellana**

**16.35 Oral Communication:**

New insights in HBMMSC migration: the response to plasma bone marrow and the role of IRE1A

**F. Da Ros**

OPEN COFFEE BREAK

## **SESSION 20 · CHRONIC MYELOID LEUKEMIA STATE OF THE ART**

Chairs: F. Castagnetti, G. Rosti, G. Saglio

**16.45** Molecular Monitoring of CML Patients: Between Old and New Tools

**S. Soverini**

**17.00** Treatment-free remission or partially treatment free remission

**M. Malagola**

**17.15** Asciminib or Ponatinib for Multiresistant Patients?

**G. Rosti**

**17.30** How I manage Blast crisis

**F. Castagnetti**



**17.45 Assessment and Management of TKI Related AOE's in CML**  
**G. Saglio**

**18.00 DISCUSSION**

**18.15 Oral Communication:**

Matrine as a potential drug candidate against Chronic Myeloid Leukemia

**A. Ishtiaq**

**18.25 Prizes and Conclusions. See you next year**

**C. Cerchione, H. Kantarjian, G. Martinelli**



[illegible]



A photograph of the dome of St. Peter's Basilica in Rome at sunset. The dome is covered in silver-colored tiles and features several small arched windows. In the background, the classical architecture of the basilica is visible, including a large quadriga statue on a pedestal. The sky is a mix of orange and purple, indicating the time is either dawn or dusk. The text "SEE YOU NEXT YEAR!" is overlaid in the upper right corner in a bold, white, sans-serif font.

SEE YOU  
NEXT  
YEAR!



# 5 soho Italy

SOCIETY OF HEMATOLOGIC ONCOLOGY

## 2023 ANNUAL CONFERENCE

### HYBRID EVENT

#### Presidents

C. Cerchione, H. Kantarjian, G. Martinelli

#### Scientific Board

C. Cerchione, N. Daver, C. DiNardo, A. Ferrajoli,  
N. Fowler, G. Garcia - Manero, E. Jabbour, T. Kadia,  
H. Kantarjian, M. Konopleva, H. Lee, G. Martinelli,  
G. Musuraca, A. Ravandi, G. Saglio, S. Verstovsek

#### Scientific Secretariat

C. Cerchione, G. Martinelli,  
G. Musuraca



**01 - 04 Oct 2023**

**A. Roma Lifestyle Hotel  
Rome, Italy**

**JOIN Us**  
Become a Member



Follow us  
**#SOHOItaly**





**SUPPORTED BY  
AN UNRESTRICTED  
EDUCATIONAL GRANT FROM**



## GOLD



## SILVER



A Menarini Group Company

## BRONZE







## Follow Us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is **#SOHOItaly**

You can use it on **Facebook, Twitter, Instagram** and **Linkedin**.

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly

@SocietyofHemOnc

@IRSTufficiale

@MDAndersonNews

@pro\_eventi

@GMartinelli2

@DottorClaudio

@DrHKantarjian

**Enjoy & Share your experience!**

Follow us





## Media Partners




Cancer Drug  
Resistance



**PHARMA**STAR<sup>★</sup>  
il Giornale online sui Farmaci

**VJ**HEMONC  
The Video Journal of Hematological Oncology

 **VuMedi**



SERVIZIO SANITARIO REGIONALE  
EMILIA ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUT  
ROMAGN LO  
PER L STUDIO  
DEI TUM RI  
DIN AMADORI